questionsmedicales.fr
Système nerveux
Système nerveux central
Encéphale
Barrière hémato-encéphalique
Barrière hémato-encéphalique : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Barrière hémato-encéphalique : Questions médicales les plus fréquentes",
"headline": "Barrière hémato-encéphalique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Barrière hémato-encéphalique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Barrière hémato-encéphalique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Encéphale",
"url": "https://questionsmedicales.fr/mesh/D001921",
"about": {
"@type": "MedicalCondition",
"name": "Encéphale",
"code": {
"@type": "MedicalCode",
"code": "D001921",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A08.186.211"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Barrière hémato-encéphalique",
"alternateName": "Blood-Brain Barrier",
"code": {
"@type": "MedicalCode",
"code": "D001812",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "William A Banks",
"url": "https://questionsmedicales.fr/author/William%20A%20Banks",
"affiliation": {
"@type": "Organization",
"name": "Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, United States; Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States."
}
},
{
"@type": "Person",
"name": "Elizabeth M Rhea",
"url": "https://questionsmedicales.fr/author/Elizabeth%20M%20Rhea",
"affiliation": {
"@type": "Organization",
"name": "Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, United States; Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States. Electronic address: meredime@uw.edu."
}
},
{
"@type": "Person",
"name": "Chenghua Gu",
"url": "https://questionsmedicales.fr/author/Chenghua%20Gu",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurobiology, Harvard Medical School, 220 Longwood Ave., Boston, MA 02115, USA. Electronic address: chenghua_gu@hms.harvard.edu."
}
},
{
"@type": "Person",
"name": "Michelle A Erickson",
"url": "https://questionsmedicales.fr/author/Michelle%20A%20Erickson",
"affiliation": {
"@type": "Organization",
"name": "Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA."
}
},
{
"@type": "Person",
"name": "Steffen E Storck",
"url": "https://questionsmedicales.fr/author/Steffen%20E%20Storck",
"affiliation": {
"@type": "Organization",
"name": "Institute for Pathobiochemistry, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Listeria monocytogenes Transmission from Donated Blood to Platelet Transfusion Recipient, Italy.",
"datePublished": "2023-07-21",
"url": "https://questionsmedicales.fr/article/37478295",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3201/eid2910.230746"
}
},
{
"@type": "ScholarlyArticle",
"name": "Performance evaluation of PLT-H (hybrid-channel platelet) under various interferences and application studies for platelet transfusion decisions.",
"datePublished": "2023-11-30",
"url": "https://questionsmedicales.fr/article/38031975",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/09537104.2023.2287064"
}
},
{
"@type": "ScholarlyArticle",
"name": "Loss of heterozygosity leading to incorrect HLA typing for platelet-transfusion refractory patient.",
"datePublished": "2022-11-25",
"url": "https://questionsmedicales.fr/article/36426572",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/trf.17189"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficiency of Platelet Transfusion in Patients with Moderate-to-Severe Chronic Kidney Disease and Thrombocytopenia.",
"datePublished": "2023-11-02",
"url": "https://questionsmedicales.fr/article/37958881",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms242115895"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion.",
"datePublished": "2023-04-17",
"url": "https://questionsmedicales.fr/article/37138863",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1031968"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Système nerveux",
"item": "https://questionsmedicales.fr/mesh/D009420"
},
{
"@type": "ListItem",
"position": 3,
"name": "Système nerveux central",
"item": "https://questionsmedicales.fr/mesh/D002490"
},
{
"@type": "ListItem",
"position": 4,
"name": "Encéphale",
"item": "https://questionsmedicales.fr/mesh/D001921"
},
{
"@type": "ListItem",
"position": 5,
"name": "Barrière hémato-encéphalique",
"item": "https://questionsmedicales.fr/mesh/D001812"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Barrière hémato-encéphalique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Barrière hémato-encéphalique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Barrière hémato-encéphalique",
"description": "Comment évaluer l'intégrité de la barrière hémato-encéphalique ?\nQuels signes indiquent une défaillance de la barrière ?\nQuels tests sanguins sont utiles pour le diagnostic ?\nLa biopsie est-elle nécessaire pour le diagnostic ?\nQuels examens neurologiques sont recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D001812?mesh_terms=Platelet+Transfusion&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Barrière hémato-encéphalique",
"description": "Quels symptômes sont associés à une barrière défaillante ?\nLa confusion mentale est-elle un symptôme ?\nDes convulsions peuvent-elles se produire ?\nQuels symptômes neurologiques sont préoccupants ?\nLa fatigue chronique est-elle liée à cette condition ?",
"url": "https://questionsmedicales.fr/mesh/D001812?mesh_terms=Platelet+Transfusion&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Barrière hémato-encéphalique",
"description": "Comment prévenir les troubles de la barrière hémato-encéphalique ?\nLes vaccinations sont-elles importantes ?\nLe contrôle de la pression artérielle aide-t-il ?\nL'alimentation joue-t-elle un rôle ?\nLe stress peut-il affecter la barrière ?",
"url": "https://questionsmedicales.fr/mesh/D001812?mesh_terms=Platelet+Transfusion&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Barrière hémato-encéphalique",
"description": "Quels traitements sont disponibles pour les troubles de la barrière ?\nLa chirurgie est-elle une option de traitement ?\nLes corticostéroïdes sont-ils utilisés ?\nY a-t-il des traitements expérimentaux ?\nComment la rééducation peut-elle aider ?",
"url": "https://questionsmedicales.fr/mesh/D001812?mesh_terms=Platelet+Transfusion&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Barrière hémato-encéphalique",
"description": "Quelles complications peuvent survenir ?\nLes AVC sont-ils une complication possible ?\nDes troubles cognitifs peuvent-ils se développer ?\nLa démence est-elle une complication ?\nLes troubles psychiatriques sont-ils possibles ?",
"url": "https://questionsmedicales.fr/mesh/D001812?mesh_terms=Platelet+Transfusion&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Barrière hémato-encéphalique",
"description": "Quels facteurs augmentent le risque de défaillance ?\nLe diabète est-il un facteur de risque ?\nL'alcoolisme influence-t-il la barrière ?\nLe tabagisme est-il un risque ?\nLes infections virales sont-elles préoccupantes ?",
"url": "https://questionsmedicales.fr/mesh/D001812?mesh_terms=Platelet+Transfusion&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'intégrité de la barrière hémato-encéphalique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie comme l'IRM et des analyses de liquide céphalorachidien sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une défaillance de la barrière ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes neurologiques, des infections ou des inflammations peuvent indiquer une défaillance."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests pour détecter des anticorps ou des marqueurs inflammatoires peuvent être effectués."
}
},
{
"@type": "Question",
"name": "La biopsie est-elle nécessaire pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, sauf dans des cas spécifiques comme les tumeurs cérébrales ou infections."
}
},
{
"@type": "Question",
"name": "Quels examens neurologiques sont recommandés ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens neurologiques complets, y compris des tests de réflexes et de coordination."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une barrière défaillante ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maux de tête, des troubles de la vision, et des changements de comportement peuvent survenir."
}
},
{
"@type": "Question",
"name": "La confusion mentale est-elle un symptôme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la confusion mentale peut résulter d'une altération de la barrière hémato-encéphalique."
}
},
{
"@type": "Question",
"name": "Des convulsions peuvent-elles se produire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des convulsions peuvent être un signe d'irritation cérébrale due à une défaillance."
}
},
{
"@type": "Question",
"name": "Quels symptômes neurologiques sont préoccupants ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des engourdissements, des faiblesses musculaires ou des troubles de l'équilibre sont préoccupants."
}
},
{
"@type": "Question",
"name": "La fatigue chronique est-elle liée à cette condition ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue chronique peut être un symptôme associé à des troubles de la barrière."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles de la barrière hémato-encéphalique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain, éviter les toxines et gérer les maladies chroniques aide."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent prévenir certaines infections qui affectent la barrière."
}
},
{
"@type": "Question",
"name": "Le contrôle de la pression artérielle aide-t-il ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bon contrôle de la pression artérielle peut réduire le risque de défaillance."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en antioxydants peut protéger la barrière hémato-encéphalique."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter la barrière ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut avoir un impact négatif sur la santé de la barrière."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles de la barrière ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments anti-inflammatoires et des thérapies ciblées."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle une option de traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie peut être nécessaire pour retirer des tumeurs ou traiter des infections."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'inflammation et améliorer la fonction de la barrière."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements expérimentaux incluent des thérapies géniques et des médicaments innovants."
}
},
{
"@type": "Question",
"name": "Comment la rééducation peut-elle aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La rééducation peut aider à restaurer les fonctions neurologiques altérées par des troubles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections, des inflammations et des troubles neurologiques graves peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les AVC sont-ils une complication possible ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une défaillance de la barrière peut augmenter le risque d'accidents vasculaires cérébraux."
}
},
{
"@type": "Question",
"name": "Des troubles cognitifs peuvent-ils se développer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cognitifs peuvent résulter d'une altération prolongée de la barrière."
}
},
{
"@type": "Question",
"name": "La démence est-elle une complication ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines formes de démence peuvent être liées à des dysfonctionnements de la barrière."
}
},
{
"@type": "Question",
"name": "Les troubles psychiatriques sont-ils possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles psychiatriques peuvent être exacerbés par des problèmes de barrière."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de défaillance ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les maladies auto-immunes et les infections sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Le diabète est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut affecter la santé de la barrière hémato-encéphalique."
}
},
{
"@type": "Question",
"name": "L'alcoolisme influence-t-il la barrière ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'alcoolisme chronique peut endommager la barrière hémato-encéphalique."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à une augmentation des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles préoccupantes ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales peuvent compromettre la barrière hémato-encéphalique."
}
}
]
}
]
}
We report Listeria monocytogenes infection in a patient in Italy who was transfused with pooled platelet concentrate. Genomic analysis revealed that L. monocytogenes isolates from the donor blood unit...
The hybrid-channel platelet counting method (PLT-H) is a new platelet counting technique proposed by Mindray of China. In this study, we aimed to evaluate the accuracy of this technique in various sit...
Management of platelet-transfusion refractory (PR) patients due to anti-HLA antibodies includes the provision of HLA-matched (HLAm) platelets (PLT) or PLTs that are negative for HLA antigens correspon...
HLA typing was performed by three methods: (1) Real-time PCR; (2) Sequence-specific oligonucleotide (SSO) typing test; and (3) Next-Generation Sequencing (NGS). Cytogenomic SNP microarray was utilized...
A 30-year-old female with newly diagnosed acute myelogenous leukemia was found to be PR secondary to HLA sensitization. A peripheral blood (PB) sample, containing 93% myeloid blast cells, was sent for...
In hematologic patients with high tumor burden, HLA homozygosity should be viewed with suspicion for potential LOH. Therefore, HLA testing should be repeated, preferably with a non-hematological sourc...
There have been relatively few studies revealing a decreased platelet count in chronic kidney disease (CKD). Although this hematological abnormality is not as well documented as renal anemia, platelet...
Platelet concentrate (PC) transfusion seeks to provide haemostasis in patients presenting severe central thrombocytopenia or severe bleeding. PCs may induce adverse reactions (AR) that can occasionall...
Corrected count increment (CCI) measurements monitor the effectiveness of platelet transfusions in haemato-oncology, but they usually fail in patients undergoing cardiac surgery. We investigated wheth...
Leukocyte-free, platelet-rich plasma was prepared from patients' blood to measure platelet counts based on patient-/donor-specific SNPs by digital PCR after DNA extraction. Platelet counts in samples ...
The digital PCR of the seven SNPs reliably quantified levels ≥0.6 G/L platelets, in good agreement with flow cytometry and without interference by other SNPs or by platelet activation. A mean 24-h CCI...
PCR of mitochondrial SNPs offers a tool to assess the survival of platelets from apheresis concentrates in cardiac surgery patients to facilitate the implementation of improved transfusion strategies....
Acute lymphoblastic leukemia (ALL) is a common hematopoietic malignancy, and platelet transfusion plays a crucial role in its treatment. This study aimed to investigate the changes in inflammatory res...
Response to prophylactic platelet transfusion is suspected to be inconsistent in critically ill patients questioning how to optimize transfusion practices. This study aimed to describe prophylactic pl...
This prospective multicentre observational study recruited patients who received at least one prophylactic platelet transfusion in one of the nine participating intensive care units for a period up to...
Poor platelet transfusion response occurred in 349 of the 472 (73.9%) prophylactic platelet transfusions and in 141/181 (77.9%) patients. The mixed-effect model identified haemoglobin at ICU admission...
In this study of critically ill patients, of whom more than half had bone marrow failure, almost three quarters of prophylactic platelet transfusions led to suboptimal platelet increment measured 18 t...
Platelet transfusion carries risk of transfusion-transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including tran...
An open label, sequential cohort study of transfusion-dependent hematology-oncology patients was conducted to compare pulmonary safety of PRPC with conventional PC (CPC). The primary outcome was the i...
By modified intent-to-treat (mITT), 1068 patients received 5277 PRPC and 1223 patients received 5487 CPC. The cohorts had similar demographics, primary disease, and primary therapy. PRPC were non-infe...
PRPC demonstrated reduced TEAMV with no excess treatment-related pulmonary morbidity....
Benefits of prophylactic platelet (PLT) transfusion before dentoalveolar surgery are unclear. This study investigated the effect of prophylactic PLT transfusions on the incidence of postoperative blee...
The cohort in this retrospective study comprised 83 patients with thrombocytopenia ≤ 75*10...
POB events were observed in 5 of 83 patients (6.0%) who had a median PLT count of 35*10...
Our data indicate that prophylactic PLT transfusions in thrombocytopenic patients with PLT counts ≤ 75*10...